Please login to the form below

Not currently logged in
Email:
Password:

Xceleron and Organon sign microdose study agreement

Xceleron collaborates with Organon on a three-compound human microdose study focusing on candidate selection for further clinical development

UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

The three selected drug candidates are all compounds from Organon' gynaecological R&D activities. The purpose of the human microdose study is to assess all important pharmacokinetic properties of the compounds, while confirming the scalability of the microdose to pharmacological dose for these compounds.

Xceleron will use its Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.

Xceleron' founder and CEO Professor Colin Garner said: "We are delighted that Organon has further demonstrated its willingness to adopt innovative approaches to drug development and are proud to add them to Xceleron' rapidly growing, international portfolio of human microdose supporters."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...
Innovation and agility
Start small but think big
Exploring the potential of agility in unlocking creativity...

Infographics